EA200601738A1 - Модифицированные белки буганины, цитотоксины и способы их применения - Google Patents

Модифицированные белки буганины, цитотоксины и способы их применения

Info

Publication number
EA200601738A1
EA200601738A1 EA200601738A EA200601738A EA200601738A1 EA 200601738 A1 EA200601738 A1 EA 200601738A1 EA 200601738 A EA200601738 A EA 200601738A EA 200601738 A EA200601738 A EA 200601738A EA 200601738 A1 EA200601738 A1 EA 200601738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
considered
methods
cell epitope
modified proteins
modified
Prior art date
Application number
EA200601738A
Other languages
English (en)
Other versions
EA010803B1 (ru
Inventor
Мэттью Бейкер
Фрэнсис Дж. Карр
Коэн Хеллендорн
Жанник Сизо
Глен Кристофер Макдональд
Джойслин Энтуистл
Дени Жорж Боск
Николя Рональд Гловер
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA200601738A1 publication Critical patent/EA200601738A1/ru
Publication of EA010803B1 publication Critical patent/EA010803B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Рассматриваются модифицированные формы белка буганина, обладающие биологической активностью и пониженной способностью активировать человеческие Т-клетки по сравнению с немодифицированным белком буганином. Рассматриваются также пептиды Т-клеточного эпитопа в буганине и модифицированные пептиды Т-клеточного эпитопа в буганине, которые обладают пониженной способностью активировать человеческие Т-клетки по сравнению с немодифицированным пептидом Т-клеточного эпитопа. Рассматриваются также цитотоксины, содержащие лиганд, связанный с раковыми клетками и присоединенный к модифицированным белкам буганинам. Рассматриваются также способы ингибирования или разрушения раковых клеток млекопитающего с использованием цитотоксинов и фармацевтических композиций для лечения рака человека.
EA200601738A 2004-03-19 2005-03-18 Модифицированные белки буганины, цитотоксины и способы их применения EA010803B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55458004P 2004-03-19 2004-03-19
US63057104P 2004-11-26 2004-11-26
PCT/CA2005/000410 WO2005090579A1 (en) 2004-03-19 2005-03-18 Modified bouganin proteins, cytotoxins and methods and uses thereof

Publications (2)

Publication Number Publication Date
EA200601738A1 true EA200601738A1 (ru) 2007-04-27
EA010803B1 EA010803B1 (ru) 2008-12-30

Family

ID=34993709

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601738A EA010803B1 (ru) 2004-03-19 2005-03-18 Модифицированные белки буганины, цитотоксины и способы их применения

Country Status (18)

Country Link
US (4) US7339031B2 (ru)
EP (1) EP1737961B1 (ru)
JP (1) JP5025460B2 (ru)
KR (1) KR101165867B1 (ru)
AU (1) AU2005224942B2 (ru)
BR (1) BRPI0508670B1 (ru)
CA (1) CA2560278C (ru)
DK (1) DK1737961T3 (ru)
EA (1) EA010803B1 (ru)
ES (1) ES2424643T3 (ru)
HK (1) HK1102306A1 (ru)
IL (1) IL177922A (ru)
MX (1) MXPA06010716A (ru)
NO (1) NO338293B1 (ru)
NZ (1) NZ550339A (ru)
PL (1) PL1737961T3 (ru)
PT (1) PT1737961E (ru)
WO (1) WO2005090579A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100417414C (zh) 2003-04-30 2008-09-10 苏黎世大学 免疫毒素在制备治疗头颈鳞状上皮细胞癌或膀胱癌药物中的应用
NZ552476A (en) 2004-06-10 2009-09-25 Viventia Biotech Inc Tumor specific antibody
CN101115771B (zh) 2005-02-03 2013-06-05 安迪拓普有限公司 人类抗体和蛋白质
US7956162B2 (en) * 2005-12-21 2011-06-07 Viventia Biotechnologies Inc. Cancer-associated antigen
US9109223B2 (en) 2005-12-23 2015-08-18 Viventia Bio, Inc. Methods for generating and screening fusion protein libraries and uses thereof
EP2079840A4 (en) * 2006-10-30 2010-06-30 Viventia Biotech Inc IMMUNOTOXIN FUSIONS COMPRISING PROTEASEPLATABLE LINKER-ASSOCIATED ANTIBODY FRAGMENT AND PLANT TOXIN
EP2423221B1 (en) * 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US8263744B2 (en) 2007-04-19 2012-09-11 Viventia Biotechnologies Inc. Binding proteins that bind to EpCAM linked to an effector molecule
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
WO2009039630A1 (en) 2007-09-27 2009-04-02 Viventia Biotech Inc. Optimized nucleic acid sequences for the expression of vb4-845
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
US9388397B2 (en) 2013-02-15 2016-07-12 Research Development Foundation Deimmunized gelonin molecules and therapies
US10059750B2 (en) 2013-03-15 2018-08-28 Angelica Therapeutics, Inc. Modified toxins
WO2014166002A1 (en) * 2013-04-12 2014-10-16 Viventia Bio Inc. Compositions and methods for detection and treatment of hepatocellular carcinoma
KR102068519B1 (ko) 2013-07-01 2020-01-21 삼성전자주식회사 저장 장치, 그것의 쓰기 방법 및 읽기 방법
WO2015048901A1 (en) 2013-10-02 2015-04-09 Viventia Bio Inc. Anti-epcam antibodies and methods of use
US20160060358A1 (en) * 2014-08-28 2016-03-03 California Institute Of Technology Induction of antigen-specific tolerance
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略
US10576163B2 (en) 2015-03-12 2020-03-03 Viventia Bio Inc. Methods of treatment for EpCAM positive bladder cancer
WO2016187571A2 (en) * 2015-05-20 2016-11-24 Viventia Bio Inc. Her2 immunotoxins and methods of using the same
AU2018347796A1 (en) 2017-10-10 2020-05-07 Medicenna Therapeutics, Inc. IL-4-fusion formulations for treatment of central nervous system (CNS) tumors
CN112823023B (zh) * 2018-08-10 2024-04-12 桑福德伯纳姆普利斯医学发现研究所 肿瘤相关巨噬细胞的结合分子及使用方法
JP7124034B2 (ja) * 2020-11-05 2022-08-23 株式会社天柳 嚥下困難者用食品組成物の製造方法
JP7488928B1 (ja) 2023-03-01 2024-05-22 積水フーラー株式会社 ホットメルト接着剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
ATE527358T1 (de) * 1997-06-06 2011-10-15 Pangenetics Bv Ribosomen inaktivierendes protein vom typ-1
JP2002507967A (ja) * 1997-06-20 2002-03-12 パンゲネチックス・ベー・ファウ 疾病治療のための抗ｃｄ４０ｌイムノトキシン
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
HUP0303199A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20060019885A1 (en) * 2002-06-11 2006-01-26 Matthew Baker Modified bryodin 1 with reduced immunogenicity
ATE320603T1 (de) 2002-06-11 2006-04-15 Merck Patent Gmbh Methode zur identifizierung und eliminierung von t-zell epitopen
CA2424255A1 (en) * 2003-03-26 2004-09-26 Claudio Di Paolo Immunotoxins
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
NZ552476A (en) 2004-06-10 2009-09-25 Viventia Biotech Inc Tumor specific antibody
WO2006066408A1 (en) * 2004-12-21 2006-06-29 Viventia Biotech Inc. Cancer specific antibody and cell surface proteins
CN101115771B (zh) * 2005-02-03 2013-06-05 安迪拓普有限公司 人类抗体和蛋白质

Also Published As

Publication number Publication date
CA2560278C (en) 2012-11-20
JP5025460B2 (ja) 2012-09-12
KR101165867B1 (ko) 2012-07-13
PT1737961E (pt) 2013-08-26
DK1737961T3 (da) 2013-08-05
NO338293B1 (no) 2016-08-08
IL177922A0 (en) 2006-12-31
MXPA06010716A (es) 2007-02-21
JP2008500811A (ja) 2008-01-17
WO2005090579A1 (en) 2005-09-29
AU2005224942B2 (en) 2011-08-11
AU2005224942A1 (en) 2005-09-29
US7750136B2 (en) 2010-07-06
ES2424643T3 (es) 2013-10-07
EP1737961B1 (en) 2013-05-08
IL177922A (en) 2011-06-30
EP1737961A1 (en) 2007-01-03
NO20064134L (no) 2006-11-08
NZ550339A (en) 2009-11-27
KR20070000494A (ko) 2007-01-02
US8716234B2 (en) 2014-05-06
BRPI0508670A (pt) 2007-08-14
EA010803B1 (ru) 2008-12-30
CA2560278A1 (en) 2005-09-29
BRPI0508670B1 (pt) 2023-01-24
US20050238642A1 (en) 2005-10-27
US20080219994A1 (en) 2008-09-11
US20150018526A1 (en) 2015-01-15
US7339031B2 (en) 2008-03-04
EP1737961A4 (en) 2008-12-17
PL1737961T3 (pl) 2013-12-31
HK1102306A1 (en) 2007-11-16
US20100254964A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
EA200601738A1 (ru) Модифицированные белки буганины, цитотоксины и способы их применения
Kang et al. Therapeutic properties and biological benefits of marine-derived anticancer peptides
EA201000424A1 (ru) Антитела к il-23
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
ATE405650T1 (de) Produktion von ganzen antikörpern in prokaryontischen zellen
ATE348632T1 (de) Prion protein peptide und deren verwendung
DE60224291D1 (de) System zur antikörperexpression und- synthese
BRPI0507169A (pt) polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
UA102099C2 (ru) Средство, предназначенное для лечения и/или профилактики аутоиммунного заболевания и образования регуляторных t-клеток
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
PE20061444A1 (es) Anticuerpo anti-mcp-1, composiciones, metodos y usos
IN2012DN02981A (ru)
BRPI0720879A2 (pt) microvesícula derivada de fermento carreador de fator de tecido (tf), composição e composição farmacêutica que a compreende, processos para a sua manufatura, proteína lipida de fator de tecido (tf) modificado, polinucleotídeo, vetor, célula hospedeira e anticorpo.
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
WO2006082304A3 (fr) Nouveaux peptides interagissant avec les membres anti-apoptotiques de la famille de proteines bcl-2 et utilisations
Mazor et al. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38
PH12015501467A1 (en) Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
Fetse et al. Discovery of cyclic peptide inhibitors targeting PD-L1 for cancer immunotherapy
Hamilton et al. Therapeutics targeting the core apoptotic machinery
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
EP1896588A4 (en) NOVEL Aβ BINDING PROTEIN, ITS PEPTIDE DERIVATIVES AND USES THEREOF
WO2005108430A3 (en) Monoclonal antibody sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM